Vera Miranda-GonÃ§alves

List of Publications by Year
in descending order

51 papers	1,825 citations	304743 22 h-index	276875 41 g-index
51 all docs	51 docs citations	51 times ranked	3125 citing authors

#	Article	IF	Citations
1	Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro-Oncology, 2013, 15, 172-188.	1.2	208
2	Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer, 2011, 11, 312.	2.6	147
3	Targeting lactate transport suppressesin vivobreast tumour growth. Oncotarget, 2015, 6, 19177-19189.	1.8	92
4	Angiogenic Potential of Gellan-Gum-Based Hydrogels for Application in Nucleus Pulposus Regeneration: In Vivo Study. Tissue Engineering - Part A, 2012, 18, 1203-1212.	3.1	89
5	Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets. Frontiers in Genetics, 2018, 9, 427.	2.3	88
6	Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas. Oncotarget, 2016, 7, 46335-46353.	1.8	81
7	The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4. Cell Cycle, 2016, 15, 1462-1470.	2.6	66
8	Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells. Cancer Letters, 2015, 365, 68-78.	7.2	65
9	Tumor Growth Suppression Induced by Biomimetic Silk Fibroin Hydrogels. Scientific Reports, 2016, 6, 31037.	3.3	62
10	CD147 and MCT1â€potential partners in bladder cancer aggressiveness and cisplatin resistance. Molecular Carcinogenesis, 2015, 54, 1451-1466.	2.7	61
11	In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas. Translational Oncology, 2013, 6, 187-IN20.	3.7	60
12	Downregulation of RKIP Is Associated with Poor Outcome and Malignant Progression in Gliomas. PLoS ONE, 2012, 7, e30769.	2.5	57
13	Differential sensitivities to lactate transport inhibitors of breast cancer cell lines. Endocrine-Related Cancer, 2014, 21, 27-38.	3.1	54
14	RKIP Inhibition in Cervical Cancer Is Associated with Higher Tumor Aggressive Behavior and Resistance to Cisplatin Therapy. PLoS ONE, 2013, 8, e59104.	2.5	52
15	Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 119, 271-282.	4.3	42
16	Antitumoural and antiangiogenic activity of Portuguese propolis in in vitro and in vivo models. Journal of Functional Foods, 2014, 11, 160-171.	3.4	34
17	Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells. Investigational New Drugs, 2019, 37, 223-237.	2.6	33
18	JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma. Cell Death and Disease, 2020, 11, 1068.	6.3	33

#	ARTICLE	IF	CITATIONS
19	Monocarboxylate transporter 1 is a key player in gliomaâ€endothelial cell crosstalk. Molecular Carcinogenesis, 2017, 56, 2630-2642.	2.7	31
20	HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors. Theranostics, 2017, 7, 717-732.	10.0	31
21	Genome-Wide DNA Methylation Profiling of Esophageal Squamous Cell Carcinoma from Global High-Incidence Regions Identifies Crucial Genes and Potential Cancer Markers. Cancer Research, 2021, 81, 2612-2624.	0.9	27
22	The component of the m6A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors. Journal of Experimental and Clinical Cancer Research, 2021, 40, 268.	8.6	27
23	Lactate Increases Renal Cell Carcinoma Aggressiveness through Sirtuin 1-Dependent Epithelial Mesenchymal Transition Axis Regulation. Cells, 2020, 9, 1053.	4.1	26
24	XIST-Promoter Demethylation as Tissue Biomarker for Testicular Germ Cell Tumors and Spermatogenesis Quality. Cancers, 2019, 11, 1385.	3.7	24
25	Portuguese propolis disturbs glycolytic metabolism of human colorectal cancer in vitro. BMC Complementary and Alternative Medicine, 2013, 13, 184.	3.7	22
26	The Critical Role of Hypoxic Microenvironment and Epigenetic Deregulation in Esophageal Cancer Radioresistance. Genes, 2019, 10, 927.	2.4	22
27	Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas. Current Cancer Drug Targets, 2016, 16, 388-399.	1.6	22
28	Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells. Oncotarget, 2017, 8, 103657-103670.	1.8	21
29	Sirtuinsâ€™ Deregulation in Bladder Cancer: SIRT7 Is Implicated in Tumor Progression through Epithelial to Mesenchymal Transition Promotion. Cancers, 2020, 12, 1066.	3.7	21
30	Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors. Cancers, 2020, 12, 2903.	3.7	20
31	Deregulation of N6-Methyladenosine RNA Modification and Its Erasers FTO/ALKBH5 among the Main Renal Cell Tumor Subtypes. Journal of Personalized Medicine, 2021, 11, 996.	2.5	20
32	Epigenetic alterations as therapeutic targets in Testicular Germ Cell Tumours : current and future application of â€˜epidrugsâ€™. Epigenetics, 2021, 16, 353-372.	2.7	19
33	The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma. Genes, 2019, 10, 264.	2.4	18
34	The Monocarboxylate Transporter Inhibitor Î±-Cyano-4-Hydroxycinnamic Acid Disrupts Rat Lung Branching. Cellular Physiology and Biochemistry, 2013, 32, 1845-1856.	1.6	17
35	Targeting lactate production and efflux in prostate cancer. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165894.	3.8	17
36	Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors. Molecular Oncology, 2021, 15, 846-865.	4.6	15

#	ARTICLE	IF	CITATIONS
37	The metabolic landscape of urological cancers: New therapeutic perspectives. Cancer Letters, 2020, 477, 76-87.	7.2	14
38	MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma. Cancers, 2021, 13, 3468.	3.7	14
39	Internalization studies on zeolite nanoparticles using human cells. Journal of Materials Chemistry B, 2018, 6, 469-476.	5.8	10
40	The Tâ€box transcription factor brachyury behaves as a tumor suppressor in gliomas. Journal of Pathology, 2020, 251, 87-99.	4.5	10
41	Targeting Germ Cell Tumors with the Newly Synthesized Flavanone-Derived Compound MLo1302 Efficiently Reduces Tumor Cell Viability and Induces Apoptosis and Cell Cycle Arrest. Pharmaceutics, 2021, 13, 73.	4.5	10
42	Downregulation of m⁶A writer complex member METTL14 in bladder urothelial carcinoma suppresses tumor aggressiveness. Molecular Oncology, 2022, 16, 1841-1856.	4.6	10
43	Differential expression of DNA methyltransferases and demethylases among the various testicular germ cell tumor subtypes. Epigenomics, 2020, 12, 1579-1592.	2.1	9
44	Volatilomics Reveals Potential Biomarkers for Identification of Renal Cell Carcinoma: An In Vitro Approach. Metabolites, 2020, 10, 174.	2.9	9
45	The Impact of [C16Pyr][Amp] on the Aggressiveness in Breast and Prostate Cancer Cell Lines. International Journal of Molecular Sciences, 2020, 21, 9584.	4.1	4
46	Cadherinâ€3 is a novel oncogenic biomarker with prognostic value in glioblastoma. Molecular Oncology, 2022, 16, 2611-2631.	4.6	4
47	Ki67 and LSD1 Expression in Testicular Germ Cell Tumors Is Not Associated with Patient Outcome: Investigation Using a Digital Pathology Algorithm. Life, 2022, 12, 264.	2.4	3
48	Anti-neoplastic and demethylating activity of a newly synthetized flavanone-derived compound in Renal Cell Carcinoma cell lines. Biomedicine and Pharmacotherapy, 2021, 141, 111681.	5.6	2
49	Cadherin switches during epithelial-mesenchymal transition: CDH4/RCAD downregulation reduces bladder cancer progression. Cellular Oncology (Dordrecht), 2022, 45, 135-149.	4.4	2
50	Metabolic regulation in urological tumors: Interplay with epigenetics and epitranscriptomics. , 2021, , 107-145.		0
51	Potential Translational Thioflavin T Methodology as a Complement of Cell-Based Assays and after Drug Exposition. International Journal of Translational Medicine, 2022, 2, 134-147.	0.4	0